These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 10584773)
41. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914 [TBL] [Abstract][Full Text] [Related]
42. An early improvement threshold to predict response and remission in first-episode schizophrenia. Schennach-Wolff R; Seemüller FH; Mayr A; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Häfner H; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Riedel M Br J Psychiatry; 2010 Jun; 196(6):460-6. PubMed ID: 20513856 [TBL] [Abstract][Full Text] [Related]
43. Risperidone long-acting injection in practice - more questions than answers? Taylor D Acta Psychiatr Scand; 2006 Jul; 114(1):1-2. PubMed ID: 16774654 [No Abstract] [Full Text] [Related]
44. [Antipsychotics in clinical practice. Treatment of the first schizophrenic episode]. Jarema M; Meder J; Araszkiewicz A; Tyszkowska M Psychiatr Pol; 2008; 42(6):841-58. PubMed ID: 19441663 [TBL] [Abstract][Full Text] [Related]
45. Induction of mania by risperidone resistant to mood stabilizers. Barkin JS; Pais VM; Gaffney MF J Clin Psychopharmacol; 1997 Feb; 17(1):57-8. PubMed ID: 9004061 [No Abstract] [Full Text] [Related]
47. High-dose treatment with haloperidol: the effect of dose reduction. Volavka J; Cooper TB; Czobor P; Lindenmayer JP; Citrome LL; Mohr P; Bark N J Clin Psychopharmacol; 2000 Apr; 20(2):252-6. PubMed ID: 10770466 [TBL] [Abstract][Full Text] [Related]
48. Rationale and guidelines for the inpatient treatment of acute psychosis. Feifel D J Clin Psychiatry; 2000; 61 Suppl 14():27-32. PubMed ID: 11154014 [TBL] [Abstract][Full Text] [Related]
49. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036 [TBL] [Abstract][Full Text] [Related]
50. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Citrome L; Meng X; Hochfeld M; Stahl SM Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738 [TBL] [Abstract][Full Text] [Related]
51. Long-acting injectable risperidone in treatment refractory patients: a 14-week open-label pilot study. Procyshyn RM; Barr AM; Flynn S; Schenk C; Ganesan S; Honer WG Schizophr Res; 2010 Nov; 123(2-3):273-5. PubMed ID: 20688481 [No Abstract] [Full Text] [Related]
52. Switching between clozapine and risperidone treatment. Gardner DM; Baldessarini RJ; Benzo J; Zarate CA; Tohen M Can J Psychiatry; 1997 May; 42(4):430-1. PubMed ID: 9161773 [No Abstract] [Full Text] [Related]
53. Nicotine-antipsychotic drug interactions and attentional performance in female rats. Rezvani AH; Levin ED Eur J Pharmacol; 2004 Feb; 486(2):175-82. PubMed ID: 14975706 [TBL] [Abstract][Full Text] [Related]
54. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474 [TBL] [Abstract][Full Text] [Related]
55. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG; Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173 [TBL] [Abstract][Full Text] [Related]
56. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859 [TBL] [Abstract][Full Text] [Related]
57. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Agid O; Schulze L; Arenovich T; Sajeev G; McDonald K; Foussias G; Fervaha G; Remington G Eur Neuropsychopharmacol; 2013 Sep; 23(9):1017-22. PubMed ID: 23706529 [TBL] [Abstract][Full Text] [Related]
58. An importance of dose in antipsychotic combination therapy for schizophrenia. Suzuki T J Clin Psychopharmacol; 2011 Jun; 31(3):399; author reply 399-400. PubMed ID: 21532376 [No Abstract] [Full Text] [Related]
59. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Emsley RA Schizophr Bull; 1999; 25(4):721-9. PubMed ID: 10667742 [TBL] [Abstract][Full Text] [Related]
60. Optimal dosing with risperidone: updated recommendations. Williams R J Clin Psychiatry; 2001 Apr; 62(4):282-9. PubMed ID: 11379843 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]